Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Cynata Cymerus

  • Home
  •  
  • Cynata Cymerus



  • Most Read
  • Latest Comments
  • Cynata recruits first patient for Phase 2 trial of stem cells for graft vs host disease
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Cynata recruits first patient for Phase 2 trial of stem cells for graft vs host disease
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Cynata recruits first patient for Phase 2 trial of stem cells for graft vs host disease
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Cynata recruits first patient for Phase 2 trial of stem cells for graft vs host disease
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Cynata recruits first patient for Phase 2 trial of stem cells for graft vs host disease
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Cynata recruits first patient for Phase 2 trial of stem cells for graft vs host disease
    Cynata recruits first patient for Phase 2 trial of stem cells for graft vs host disease
    • News

  • Cynata Therapeutics advances Stem Cell Therapy for rare disease with Phase 2 recruitment underway
    Cynata Therapeutics advances Stem Cell Therapy for rare disease with Phase 2 recruitment underway
    • News

  • Cynata teams up with Leiden University Medical Center to test its stem cell solution on kidney transplant patients
    Cynata teams up with Leiden University Medical Center to test its stem cell solution on kidney transplant patients
    • News

  • Cynata to tackle common transplant side effect with lead drug CYP-001
    Cynata to tackle common transplant side effect with lead drug CYP-001
    • News

  • Body of evidence grows for Cynata’s stem cell production platform
    Body of evidence grows for Cynata’s stem cell production platform
    • News

  • Cynata recruits first patient for Phase 2 trial of stem cells for graft vs host disease
    • News

    Cynata recruits first patient for Phase 2 trial of stem cells for graft vs host disease

    Aussie clinical stage biotech company Cynata Therapeutics (ASX: CYP) has marked a milestone in its Phase 2 clinical trial of CYP-001 for high-risk acute graft versus host disease (aGvHD) with the enrolment and treatment of its first patient. High-risk acute graft versus host disease (aGvHD) is a serious complication that can occur after a stem

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.